Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy.

Shi, Jing

Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy. [electronic resource] - Journal for immunotherapy of cancer 09 2019 - 246 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

2051-1426

10.1186/s40425-019-0725-7 doi


Animals
Antineoplastic Agents--pharmacology
Apoptosis
CD8-Positive T-Lymphocytes--drug effects
Cell Proliferation
Drug Therapy, Combination
Flavones--pharmacology
Humans
Immunotherapy
Indoleamine-Pyrrole 2,3,-Dioxygenase--antagonists & inhibitors
Kynurenine--metabolism
Lymphocyte Activation--immunology
Melanoma--drug therapy
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Mice, Transgenic
Receptors, Aryl Hydrocarbon--antagonists & inhibitors
Triazoles--pharmacology
Tryptophan--pharmacology
Tumor Cells, Cultured
Tumor Microenvironment--drug effects